STOCKHOLDERS' EQUITY

3 Months Ended

May 31, 2021

NOTE 12 – STOCKHOLDERS’ EQUITY

Stock-based compensation expense is included in the following captions of the condensed consolidated statements of comprehensive loss (in thousands):

	Three Months Ended
	May 31,
	2021			2020
Cost of revenues	$	(6	)	$	143
Research and development		710			576
Selling and marketing		644			384
General and administrative		1,060			1,269
Restructuring		-			875
Other non-operating expense		64			-
	$	2,472		$	3,247

Changes in our outstanding stock options during the three months ended May 31, 2021 were as follows (options in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted average remaining contractual life (years)		Aggregate intrinsic value
Outstanding at February 28, 2021		778		$	16.01		6.0
Granted		—			—
Exercised		(33	)		7.53
Forfeited or expired		(76	)		16.49
Outstanding at May 31, 2021		669		$	16.37		6.1	$	472
Exercisable at May 31, 2021		459		$	16.39		5.3	$	118

Changes in our outstanding restricted stock shares, performance stock units (“PSUs”) and restricted stock units (“RSUs”) during the three months ended May 31, 2021 were as follows (restricted shares, PSUs and RSUs in thousands):

	Number of Restricted Shares, PSUs and RSUs			Weighted Average Grant Date Fair Value		Shares Retained to Cover Statutory Minimum Withholding Taxes
Outstanding at February 28, 2021		3,053		$	10.61
Granted		46			12.63
Vested		(205	)		12.06		82
Forfeited		(149	)		11.05
Outstanding at May 31, 2021		2,745		$	10.51

As of May 31, 2021, there was $18.8 million of total unrecognized stock-based compensation cost related to outstanding nonvested equity awards that is expected to be recognized as an expense over a weighted-average remaining vesting period of 3.8 years.